Skip to main content
    R

    Roivant Sciences Ltd (ROIV)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $33.35
    -1.24 (-3.58%)

    Market Cap: $24.99B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    62%(13/21)
    Avg Surprise
    +2.24%
    Streak
    4 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.45
    Range$-0.59 - $-0.35
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.40-13.6%
    60d ago$-0.40-13.6%
    30d ago$-0.450.0%
    7d ago$-0.450.0%
    Current$-0.45
    Revenue Consensus
    $4M
    Range$0 - $8M
    11 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.41
    Range$-0.53 - $-0.35
    3 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.36-13.0%
    60d ago$-0.36-13.0%
    30d ago$-0.410.0%
    7d ago$-0.410.0%
    Current$-0.41
    Revenue Consensus
    $12M
    Range$0 - $27M
    11 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Mar 27EST
    		-$-0.36---
    Dec 26EST
    		-$-0.41---
    Sep 26EST
    		-$-0.45---
    Jun 26
    Reported Aug 6
    		$-0.45$-0.45+0.00%Beat-80.0%
    Mar 26
    Reported May 20
    		$-0.32$-0.35+8.57%Beat-10.3%
    Dec 25
    Reported Feb 6
    		$-0.24$-0.31+22.58%Beat-20.0%
    Sep 25
    Reported Nov 10
    		$-0.28$-0.30+6.67%Beat+6.7%
    Jun 25
    Reported Aug 11
    		$-0.25$-0.23-8.70%Miss-38.9%
    Mar 25
    Reported May 29
    		$-0.29$-0.26-10.31%Miss-52.6%
    Dec 24
    Reported Feb 10
    		$-0.20$-0.24+16.67%Beat+4.8%
    Sep 24
    Reported Nov 12
    		$-0.30$-0.24-25.00%Miss-3.4%
    Jun 24
    Reported Aug 8
    		$-0.18$-0.24+25.00%Beat+35.7%
    Mar 24
    Reported May 30
    		$-0.19$-0.30+36.67%Beat+5.0%
    Dec 23
    Reported Feb 13
    		$-0.21$-0.27+22.22%Beat+50.0%
    Sep 23
    Reported Nov 13
    		$-0.29$-0.27-7.41%Miss+9.4%
    Jun 23
    Reported Aug 14
    		$-0.28$-0.28+0.00%Beat+6.7%
    Mar 23
    Reported Jun 28
    		$-0.20$-0.36+44.44%Beat+25.9%
    Dec 22
    Reported Feb 13
    		$-0.42$-0.32-31.25%Miss-2.4%
    Sep 22
    Reported Nov 14
    		$-0.32$-0.34+5.88%Beat+0.0%
    Jun 22
    Reported Aug 15
    		$-0.30$-0.28-7.14%Miss-7.1%
    Mar 22
    Reported Jun 28
    		$-0.27$-0.32+15.63%Beat-173.0%
    Dec 21
    Reported Feb 14
    		$-0.41$-0.24-70.83%Miss-4000.0%
    Sep 21
    Reported Nov 15
    		$-0.32$-0.36+11.11%Beat-
    Jun 21
    Reported Aug 10
    		$-0.28$-0.26-7.69%Miss-1754.3%
    Mar 21
    Reported May 20
    		$0.37N/AN/ABeat+245.4%
    Dec 20
    Reported Mar 22
    		$-0.01N/AN/ABeat-
    Sep 20
    Reported Nov 19
    		$0.00$0.00N/ABeat-
    Mar 20
    Reported Jun 30
    		$-0.02$0.00N/AMiss-
    Dec 19
    Reported Mar 31
    		$-0.25$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-25.85EV/EBITDAN/A
    Price/FCF-28.93xFCF Yield-3.46%
    Profitability
    Profit Margin0.00%Operating Margin-25408.00%
    ROE-8.52%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio16.72xQuick Ratio16.72x
    Trading Statistics
    Beta1.10Avg Volume7.40M
    52-Week High$42.5052-Week Low$16.88

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$35.14
    SMA 20$36.51
    SMA 50$36.70
    SMA 200$30.61
    EMA 10$35.10
    EMA 20$35.93
    EMA 50$36.06
    EMA 200$30.68

    MACD

    Line: -0.83Signal: -0.47Hist: -0.36

    ADX

    ADX: 16.4+DI: 18.8-DI: 31.7

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down100.0
    PSAR$37.58

    Bollinger Bands

    Upper Band$40.31
    Lower Band$32.71
    %B Position2079%(Upper)
    Band Width0.08

    RSI (14-Day)

    Neutral
    35.1

    Momentum Oscillators

    Stoch %K21.0
    Stoch %D21.0
    Williams %R-97.8
    ROC (10d)-8.6%
    Momentum-3.15
    CCI (20d)-120.8
    MFI (14d)39.1

    Volatility Measures

    ATR (14d)$1.33(4.0%)
    StdDev (20d)1.90
    Hist Vol31.4%(Moderate)

    Volume Flow

    VWAP$33.84
    OBV275.1M
    AD Line133.1M
    CMF (20d)-0.399

    Volume Metrics

    Avg Vol (20d)7.4M
    Vol Ratio0.9x
    VWMA (20d)$37.18

    Pivot Points

    R3$36.01
    R2$35.71
    R1$35.15
    Pivot Point$34.85
    S1$34.29
    S2$33.99
    S3$33.43

    Advanced Oscillators

    TSI-16.83
    Ultimate Osc43.5
    KST-62.33

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.44M$2.52M$2.00M$1.57M$2.17M$7.57M$9.02M$4.47M$7.99M$-8,121,000$15.56M$3.65M
    Cost of Revenue$0$-154,000$0$0$0$-213,000$0$0$213,000$4.41M$0$0
    Gross Profit$1.44M$2.67M$2.00M$1.57M$2.17M$7.78M$9.02M$4.47M$7.78M$-8,121,000$15.56M$3.65M
    Operating Expenses$367.44M$-412,566,000$341.15M$307.80M$287.09M$292.75M$283.40M$346.19M$110.01M$132.00M$-5,111,893,000$217.54M
    R&D$202.02M$198.94M$165.38M$164.57M$152.92M$145.24M$141.59M$143.07M$120.51M$91.84M$108.15M$128.74M
    SG&A$165.53M$158.25M$175.07M$143.13M$134.02M$147.09M$141.54M$202.88M$99.89M$43.20M$128.17M$88.58M
    Operating Income$-365,993,000$415.24M$-339,153,000$-306,233,000$-284,922,000$-284,965,000$-274,381,000$-341,713,000$-102,235,000$-140,119,000$5.13B$-213,891,000
    Interest Income$73.56M$26.29M$64.86M$173.84M$29.20M$70.63M$40.54M$118.15M$87.35M$114.78M$21.49M$-14,196,000
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$27.52M
    Income Before Tax$-294,564,000$454.10M$-290,369,000$-159,044,000$-269,262,000$-203,054,000$-234,513,000$-224,383,000$-19,640,000$-18,190,000$5.15B$-241,406,000
    Income Tax Expense$-3,958,000$98.35M$23.33M$7.00M$4.65M$49.32M$-25,568,000$12.46M$11.96M$-5,850,000$22.36M$3.24M
    Net Income$-290,606,000$355.74M$-313,701,000$-166,039,000$-273,911,000$-252,375,000$118.08M$-279,924,000$57.49M$-182,496,000$5.07B$-331,118,000
    EBITDA$-373,214,000$421.54M$-363,259,000$-341,787,000$-308,422,000$-287,915,000$-301,397,000$-362,725,000$-102,110,000$-136,660,000$5.14B$-221,623,000
    EBIT$-368,123,000$427.81M$-355,227,000$-332,886,000$-298,459,000$-273,685,000$-275,050,000$-342,531,000$-106,993,000$-141,885,000$5.13B$-227,210,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ROIV

    News

    Roivant Sciences Ltd. (ROIV) Stock forecasts

    Argus has lowered its target price for Roivant Sciences Ltd. (ROIV) to $38.00. Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company focused on improving healthcare delivery. The current price of ROIV...

    Yahoo Finance UK•10/15/26•Somewhat-Bearish

    Form 4 Roivant Sciences Ltd.: Eric Venker (President & Immunovant CEO) For: 30 September

    This article reports on a Form 4 filing for Roivant Sciences Ltd., detailing transactions made by Eric Venker, who serves as President and CEO of Immunovant. The filing is for the period ending September 30.

    Investing.com Nigeria•10/13/26•Neutral

    (ROIV) Movement Within Algorithmic Entry Frameworks

    This article analyzes Roivant Sciences Ltd. (NASDAQ: ROIV) through algorithmic entry frameworks, highlighting weak near and mid-term sentiment but a positive long-term outlook. It provides three institutional trading...

    Stock Traders Daily•10/13/26•Bearish

    Here’s How Much You Would Have Made Owning Roivant Sciences Stock In The Last 5 Years

    Roivant Sciences (NASDAQ: ROIV) has significantly outperformed the market over the last five years, with an annualized return of 41.86%. An initial investment of $1000 in ROIV stock five years ago would now be worth...

    Benzinga•10/13/26•Bullish

    Form 4 Roivant Sciences Ltd.: Mayukh Sukhatme (Director, President & CIO) For: 30 September

    This article reports on a Form 4 filing for Roivant Sciences Ltd., indicating that Mayukh Sukhatme, Director, President & CIO...

    Investing.com Canada•10/13/26•Neutral

    ROIV Valuation and Fair Value

    P/E
    -25.9x
    P/FCF
    -28.9x
    P/B
    5.7x
    See GNG's fair value

    ROIV Profitability: Margins, ROIC and FCF

    Gross margin
    102.0%
    Operating margin
    -25408.0%
    Net margin
    0.0%
    ROE
    -8.5%
    FCF margin
    -11032.0%
    FCF yield
    -3.5%

    ROIV Competitors

    CompanyTicker
    Quest Diagnostics IncorporatedDGX
    Koninklijke Philips NV ADRPHG
    Laboratory Corporation of America HoldingsLH
    United Therapeutics CorporationUTHR
    West Pharmaceutical Services IncWST
    Genmab ASGMAB
    Zoetis IncZTS
    Incyte CorporationINCY

    Sector: Healthcare

    ROIV Analyst Ratings

    Consensus
    Buy
    Analysts
    13
    Strong Buy
    2
    Buy
    10
    Hold
    1
    Sell
    0
    Strong Sell
    0

    ROIV Bull Case vs Bear Case

    Bull case

    • 92.3% of ROIV's analyst ratings are Buy or Strong Buy.

    Bear case

    • ROIV's quarterly revenue changed -33.5% year over year.

    ROIV Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    1.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.45
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 3 down

    Frequently Asked Questions About ROIV

    Does ROIV pay dividends?

    Roivant Sciences Ltd (ROIV) does not currently pay a regular dividend.

    What is ROIV's market cap?

    Roivant Sciences Ltd (ROIV) has a market capitalization of $24.99B with a current stock price of $33.35.

    Related stocks

    Sector: Healthcare

    All stocks starting with R

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In